As Ranking Member McCaskill noted in a recent report entitled, "Fueling an Epidemic: Insys Therapeutics and the Systemic Manipulation of Prior Authorization," Insys revenues tripled and profits rose 45 percent between 2013 and 2015.
McCaskill highlights Insys's financial growth amid opioid crisis concerns.
Share
More from Claire McCaskill
This is really, really bad. What they’re saying is, if you criticize the president of the United States, as an elected member of Congress, we will silence you.
I think that, fundamentally, voters do understand that we have very, very low unemployment. They see it in their families, that everybody has jobs, everybody can get jobs, their jobs are paying slightly better.
There is an over-classification problem, and I was surprised Secretary Gates didn't mention it.
Other voices in this conversation
